11-05 :: May/June 2011


nanotimes News in Brief


Researchers from University of Toronto, Canada, and Yunnan University, China, demonstrate a chlorinated ITO transparent electrode with a work function of >6.1 eV that provides a direct match to the energy-levels of the active light-emitting mate- rials in state-of-the-art OLEDs. A highly simplified green OLED with a maximum external quantum efficiency (EQE) of 54% and power efficiency of 230 lumens per watt using out-coupling enhance- ment was demonstrated, as were EQE of 50% and power efficiency of 110 lumens per watt at 10,000 candela per square meter. © Science


M. G. Helander, Z. B. Wang, J. Qiu, M. T. Greiner, D. P. Puzzo, Z. W. Liu, Z. H. Lu: Chlorinated Indium Tin Oxide Electrodes with High Work Function for Organic Device Compatibility, In: Science Express, April 14, 2011, DOI:10.1126/science.1202992: http://dx.doi.org/10.1126/science.1202992


65


Benjamin Diop-Frimpong, Vikash P. Chauhan, Stephen Krane, Yves Boucher, and Rakesh K. Jain: Losartan inhi- bits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors, In: PNAS, Vol. 108(2011), No. 7, February 15, 2011, Pages 2909-2914, DOI:10.1073/pnas.1018892108: http://dx.doi.org/10.1073/pnas.1018892108


U.S. researchers examined high-temperature copper oxide superconductors. Utpal Chatterjee, Dingfei Ai, Junjing Zhao, Stephan Rosenkranz, Adam Kaminski, Helene Raffy, Zhizhong Li, Kazuo Kadowaki, Mohit Randeria, Michael R. Norman, and J. C. Campuzano: Electronic phase diagram of high- temperature copper oxide superconductors, In: PNAS Early Edition, May 23, 2011, DOI:10.1073/pnas.1101008108: http://dx.doi.org/10.1073/pnas.1101008108


U.S. researchers tested whether losartan – a clini- cally approved angiotensin II receptor antagonist with noted antifibrotic activity – can enhance the penetration and efficacy of nanomedicine. They found that losartan inhibited collagen I produc- tion by carcinoma-associated fibroblasts isolated from breast cancer biopsies. Additionally, it led to a dose-dependent reduction in stromal collagen in desmoplastic models of human breast, pancreatic, and skin tumors in mice. Furthermore, losartan improved the distribution and therapeutic efficacy of intratumorally injected oncolytic herpes simplex viruses. © PNAS


Researchers at MIT and Brigham and Women’s Hospital, USA, have shown that they can deliver the cancer drug cisplatin much more effectively and safely in a form that has been encapsulated in a nanoparticle targeted to prostate tumor cells and is activated once it reaches its target.


Using the new particles, the researchers were able to successfully shrink tumors in mice, using only one-third the amount of conventional cisplatin needed to achieve the same effect. That could help reduce cisplatin’s potentially severe side effects,


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95